Ecstasy assay

For the quantitative in vitro determination of Ecstasy in urine. This product is suitable for automated, semi-automated and manual use.

SKU: DA4014 Categories: , , , , , , Method: Homogeneous enzyme immunoassay Format: Liquid Size: R1 2 x 16.9ml, R2 2 x 8ml Assay Range: Refer to kit insert Working Stability: Stable to expiry date when stored at +2 to +8°C. Onboard stability of approx. 28 days at +10°C Available Applications: RX daytona, RX daytona+, RX imola, RX monaco Tags: , , , ,

$1,536.48

In stock

Quantity

$1,536.48

In stock

Description

Intended Use

For the quantitative in vitro determination of Ecstasy in urine. This product is suitable for automated, semi-automated and manual use.

Clinical Significance 

Ecstasy drugs are a group of amphetamine derivatives, including MDMA (3,4-methylenedioxymethamphetamine), MDA (3,4-methylenedioxyamphetamine), and MDEA
(3,4-methylenedioxyethylamphetamine). They are central nervous system (CNS) stimulants. At light dose ecstasy drugs produce euphoria, and increase self-awareness. However, they are popularly abused for their psychotropic effects and at high doses and become hallucinogenic and cause loss of behaviour control. Toxic overdose causes depression, uncontrolled body fluid excretion, cardiac arrhythmias, and sleep disorder. Since there is no known medical application of ecstasy drugs with high abuse potential, US DEA list both MDMA and MDA as schedule 1 drugs. After ingestion of the drug, MDMA is known to metabolise to MDA by de-methylation.

Within the human body, most of the drug is eliminated through urinary excretion. Most of the urinary excretions include mono- and dihydroxy derivatives which appear as glucuronide conjugates. Detection of MDMA or its metabolites in urine indicates use of ecstasy.

Available Applications

  • RX daytona
  • RX daytona+
  • RX imola
  • RX monaco

Product Specifications

Product Specifications

Product availability may vary from country to country